With the release of the revised USP <797> guidance, it is important to revisit some of the basics of sterile compounding. The Section of Inpatient Care Practitioner’s SAG on Compounding Practice has developed a three-part series that will cover differing definitions of compounding, beyond use dates (BUDs), and changes from low, medium, and high risk compounding categories. In this second episode of the series, speakers will discuss details around beyond use dating assignments and how that applies to various types of products in our compounding practice.
SPEAKERS
Kevin N. Hansen, PharmD, MS, BCSCP, (he/him) is the pharmacy director for the 503B program at Premier Inc. Dr. Hansen earned his Doctor of Pharmacy degree from LECOM and completed a PGY1/PGY2 HSPAL residency program at the University of North Carolina Medical Center. He received a Master of Science degree in Pharmaceutical Sciences with a specialization in health-system pharmacy administration from the UNC Eshelman School of Pharmacy. He is board certified through the Board of Pharmacy Specialists in sterile compounding.
Terry Laurila, MS, RPh, BCSCP, (he/him) is the home infusion/homecare pharmacy manager for Nationwide Children's Hospital in Columbus, Ohio. He graduated from The Ohio State University with his BS and MS in hospital pharmacy administration Managment with PGY2 residency at Mount Caramel Medical Center, Columbus, Ohio. He has been a hospital director of pharmacy as well involved in sterile compounding for over 30 years in both the for-profit Home Infusion national companies as well as Hospital based.
Kayleigh Thompson, PharmD, BCPS, BCCCP, (she/her) completed her Doctor of Pharmacy from The University of Texas at Austin College of Pharmacy followed by her PGY1 Pharmacy Practice and PGY2 Critical Care Residencies. She has previously worked as an emergency medicine and ICU clinical specialist in multiple adult community hospitals before becoming the Pharmacy Operations Manager at Arkansas Children’s Northwest, a growing community pediatric hospital.
Jim Lund, PharmD, MS, BCSCP, (he/him) is a senior director at Visante, Inc. and has experience in all aspects of inpatient pharmacy, including operational performance improvement, strategic planning, automation optimization, centralized service center (CSC) design and buildout, and pharmacy supply chain. Jim’s practice interests include the use of automation and technology to enhance patient safety and efficiency of pharmacy operations, strategic planning, leadership development, facility planning, and pharmacy technician practice advancement.
IN THIS SERIES
Compounding Conundrums: Compounding, What it IS and What it ISN'T
Compounding Conundrums: Beyond-Use Date, what a BUD IS and what a BUD ISN’T